Clinical and biological characteristics of the 31 ET patients included in the study
Patient . | Age at diagnosis . | Sex . | CALR mutation . | %CALR at initiation of IFNα . | %CALR at lowest . | Additional mutations . | Best HR . | IFNα treatment duration (mo) . | MR . |
---|---|---|---|---|---|---|---|---|---|
#1 | 48 | M | Type 1 | 46 | 3 | CHR | 30 | PMR | |
#2 | 29 | F | Type 2 | 50 | 5 | CHR | 97 | PMR | |
#3 | 52 | F | Type 2 | 43 | 14 | CHR | 37 | PMR | |
#4 | 43 | M | Type 1 | 33 | 38 | CHR | 19 | No | |
#5 | 14 | F | Type 1 | 49 | 42 | CHR | 12 | No | |
#6 | 25 | F | Type 1 | 50 | 44 | CHR | 38 | No | |
#7 | 54 | F | Q365fs*50 | 44 | 26 | IDH2 p.R140Q | CHR | 19 | mMR |
#8 | 45 | M | Type 1 | 20 | 10 | CHR | 22 | PMR | |
#9 | 55 | M | Type 2 | 35 | 17 | CHR | 46 | PMR | |
#10 | 39 | F | Q365fs*50 | 47 | 47 | PHR | 36 | No | |
#11 | 53 | F | Type 1 | 33 | 27 | PHR | 14 | No | |
#12 | 52 | F | Type 2 | 13 | 5 | CHR | 13 | PMR | |
#13 | 37 | M | Type 2 | 35 | 36 | CHR | 14 | No | |
#14 | 44 | M | K375fs*49 | 51 | 48 | CHR | 24 | No | |
#15 | 32 | F | Type 2 | 41 | 3 | CHR | 30 | PMR | |
#16 | 33 | F | Type 1 | 32 | 16 | CHR | 6 | PMR | |
#17 | 26 | M | Type 2 | 44 | 56 | ASXL1 p.R628fs*; IDH2 p.R140Q | CHR | 52 | No |
#18 | 35 | F | p.E364fs*55 | 19 | 26 | TET2 p.I1160N | PHR | 67 | No |
#19 | 42 | F | p,E383fs*48 | 17 | 0 | CHR | 20 | CMR | |
#20 | 49 | F | Type 1 | 55 | 35 | ASXL1 p.Q778* | CHR | 30 | mMR |
#21 | 38 | F | Type 1 | 33 | 23 | CHR | 51 | mMR | |
#22 | 19 | F | Type 1 | 58 | 43 | CHR | 30 | mMR | |
#23 | 28 | F | Type 2 | 41 | 28 | TP53 H365Y | CHR | 67 | mMR |
#24 | 22 | F | A382fs*48 | NA | NA | PHR | 57 | ND | |
#25 | 50 | F | Type 1 | 37 | 18 | CHR | 48 | PMR | |
#26 | 30 | F | Type 1 | 40 | 0 | CHR | 8 | CMR | |
#27 | 54 | F | Type 2 | 22 | 15 | ASXL1 p.G646fs*12 | CHR | 35 | mMR |
#28 | 27 | M | Type 2 | 40 | 20 | CHR | 53 | PMR | |
#29 | 49 | M | Type 1 | 45 | 49 | PHR | 72 | No | |
#30 | 58 | M | Type 1 | 32 | 31 | PHR | 5 | No | |
#31 | 46 | M | Type 1 | 46 | 22 | PHR | 19 | PMR |
Patient . | Age at diagnosis . | Sex . | CALR mutation . | %CALR at initiation of IFNα . | %CALR at lowest . | Additional mutations . | Best HR . | IFNα treatment duration (mo) . | MR . |
---|---|---|---|---|---|---|---|---|---|
#1 | 48 | M | Type 1 | 46 | 3 | CHR | 30 | PMR | |
#2 | 29 | F | Type 2 | 50 | 5 | CHR | 97 | PMR | |
#3 | 52 | F | Type 2 | 43 | 14 | CHR | 37 | PMR | |
#4 | 43 | M | Type 1 | 33 | 38 | CHR | 19 | No | |
#5 | 14 | F | Type 1 | 49 | 42 | CHR | 12 | No | |
#6 | 25 | F | Type 1 | 50 | 44 | CHR | 38 | No | |
#7 | 54 | F | Q365fs*50 | 44 | 26 | IDH2 p.R140Q | CHR | 19 | mMR |
#8 | 45 | M | Type 1 | 20 | 10 | CHR | 22 | PMR | |
#9 | 55 | M | Type 2 | 35 | 17 | CHR | 46 | PMR | |
#10 | 39 | F | Q365fs*50 | 47 | 47 | PHR | 36 | No | |
#11 | 53 | F | Type 1 | 33 | 27 | PHR | 14 | No | |
#12 | 52 | F | Type 2 | 13 | 5 | CHR | 13 | PMR | |
#13 | 37 | M | Type 2 | 35 | 36 | CHR | 14 | No | |
#14 | 44 | M | K375fs*49 | 51 | 48 | CHR | 24 | No | |
#15 | 32 | F | Type 2 | 41 | 3 | CHR | 30 | PMR | |
#16 | 33 | F | Type 1 | 32 | 16 | CHR | 6 | PMR | |
#17 | 26 | M | Type 2 | 44 | 56 | ASXL1 p.R628fs*; IDH2 p.R140Q | CHR | 52 | No |
#18 | 35 | F | p.E364fs*55 | 19 | 26 | TET2 p.I1160N | PHR | 67 | No |
#19 | 42 | F | p,E383fs*48 | 17 | 0 | CHR | 20 | CMR | |
#20 | 49 | F | Type 1 | 55 | 35 | ASXL1 p.Q778* | CHR | 30 | mMR |
#21 | 38 | F | Type 1 | 33 | 23 | CHR | 51 | mMR | |
#22 | 19 | F | Type 1 | 58 | 43 | CHR | 30 | mMR | |
#23 | 28 | F | Type 2 | 41 | 28 | TP53 H365Y | CHR | 67 | mMR |
#24 | 22 | F | A382fs*48 | NA | NA | PHR | 57 | ND | |
#25 | 50 | F | Type 1 | 37 | 18 | CHR | 48 | PMR | |
#26 | 30 | F | Type 1 | 40 | 0 | CHR | 8 | CMR | |
#27 | 54 | F | Type 2 | 22 | 15 | ASXL1 p.G646fs*12 | CHR | 35 | mMR |
#28 | 27 | M | Type 2 | 40 | 20 | CHR | 53 | PMR | |
#29 | 49 | M | Type 1 | 45 | 49 | PHR | 72 | No | |
#30 | 58 | M | Type 1 | 32 | 31 | PHR | 5 | No | |
#31 | 46 | M | Type 1 | 46 | 22 | PHR | 19 | PMR |
F, female; M, male; ND, not determined; No, absence of MR.